These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9790165)

  • 41. Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
    Bokszanska A; Martin G; Vanstraelen M; Holt G; Bouras N; Taylor D
    Int Clin Psychopharmacol; 2003 Sep; 18(5):285-91. PubMed ID: 12920389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment refractory schizophrenia: how should we proceed?
    Sharif ZA
    Psychiatr Q; 1998; 69(4):263-81. PubMed ID: 9793107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two new atypical antipsychotics: advantages and disadvantages.
    Lemon MD
    S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957
    [No Abstract]   [Full Text] [Related]  

  • 44. Olanzapine: a novel atypical neuroleptic agent.
    Reus VI
    Lancet; 1997 May; 349(9061):1264-5. PubMed ID: 9142055
    [No Abstract]   [Full Text] [Related]  

  • 45. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
    Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW
    Arch Gen Psychiatry; 2002 Nov; 59(11):1021-6. PubMed ID: 12418935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weight gain and antipsychotic medications.
    Aquila R; Emanuel M
    J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
    [No Abstract]   [Full Text] [Related]  

  • 47. Hyperprolactinemia and male sexual dysfunction.
    Dickson RA; Glazer WM
    J Clin Psychiatry; 1999 Feb; 60(2):125. PubMed ID: 10084644
    [No Abstract]   [Full Text] [Related]  

  • 48. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.
    Patel NC; Dorson PG; Edwards N; Mendelson S; Crismon ML
    Psychiatr Serv; 2002 Jul; 53(7):891-3. PubMed ID: 12096177
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
    Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
    J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
    Kasper S; Hale A; Azorin JM; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
    [No Abstract]   [Full Text] [Related]  

  • 52. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
    Fanous A; Lindenmayer JP
    J Clin Psychopharmacol; 1999 Jun; 19(3):275-6. PubMed ID: 10350037
    [No Abstract]   [Full Text] [Related]  

  • 53. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
    de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
    Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
    Harvey PD; Napolitano JA; Mao L; Gharabawi G
    Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Agranulocytosis and neutropenia with typical and atypical neuroleptics.
    Hong X; Wang X
    Am J Psychiatry; 2001 Oct; 158(10):1736-7. PubMed ID: 11579015
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
    Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
    Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
    [No Abstract]   [Full Text] [Related]  

  • 58. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
    Garyfallos G; Dimelis D; Kouniakis P; Sidiropoulos N; Karastergiou A; Lavrentiadis G; Giouzepas J; Fokas K
    Eur Psychiatry; 2003 Oct; 18(6):320-1. PubMed ID: 14611929
    [No Abstract]   [Full Text] [Related]  

  • 59. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():41-5. PubMed ID: 9766619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.